Mapping the Path to Sustainable Rare Disease Access in APAC
Situation A global biopharmaceutical company specializing in rare diseases was exploring expansion into select Asia-Pacific (APAC) markets and needed to determine whether its products could be made accessible to patients in markets with limited public reimbursement and private insurance coverage. The company needed a clear view of patient affordability, available funding mechanisms, and the broader … Continued